EUVIMEDEUVIMED entdecken
Crossref

Clinical Characteristics of Coexistent Chronic Myeloid Leukemia and BCR::ABL1 Negative Myeloproliferative Neoplasms: A Retrospective Study

Yanan Cai iD, Zefeng Xu, Shiqiang Qu, Lijuan Pan, Qingyan Gao, Meng Jiao, Songyang Zhao, Fuhui Li, Ningning Liu, Zunmin Zhu, Bing Li iD, Zhijian Xiao iD und 1 weitere

Hematological Oncology · 2026

DOI: 10.1002/hon.70273 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, 2026. Verfasst von Yanan Cai und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, National Clinical Research Center for Blood Diseases, Institute …. Hauptthemen laut MEDLINE: Fusion Proteins, bcr-abl, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Proto-Oncogene Proteins c-abl. Die Arbeit nennt 21 Literaturangaben. Gefördert von: National Natural Science Funds, Foundation of Tianjin Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coexistent chronic myeloid leukemia (CML) and BCR::ABL1 ‐negative myeloproliferative neoplasms (MPN) are rare. We aimed to evaluate their clinical and therapeutic profiles. We retrospectively evaluated 36 institutional patients with coexistent CML and BCR::ABL1 ‐negative MPN (Cohort A) and systematically reviewed 244 published cases (Cohort B). Patients were categorized by diagnostic sequence: prior CML, prior BCR::ABL1 ‐negative MPN, or concurrent presentation. BCR::ABL1 p210 and JAK2V617 F aberrations predominantly co‐occurred. Diagnoses in Cohort A were mostly concurrent (77.8%), whereas Cohort B predominantly featured prior BCR::ABL1 ‐negative MPN (43.0%), followed by concurrent diagnoses (35.7%) and prior CML (21.3%). In Cohort B, myelofibrosis was significantly more prevalent in prior BCR::ABL1 ‐negative MPN compared to those with prior CML or concurrent diagnoses (56.2% vs. 26.9% vs. 35.6%, respectively; p = 0.007). Persistent, unexplained cytosis despite active therapy triggered secondary mutation cross‐screening in both cohorts. In Cohort A, exploratory survival analysis suggested a potential trend toward shorter overall survival in prior BCR::ABL1 ‐negative MPN compared to concurrent diagnoses (90.5 months vs. not reached, p = 0.032). Multivariable analysis of Cohort B identified prior BCR::ABL1 ‐negative MPN as an independent adverse predictor for major or deeper molecular responses (OR = 0.412, 95% CI: 0.197–0.861, p = 0.018), while tyrosine kinase inhibitor (TKI)‐based therapy was favorable (OR = 9.74, 95% CI: 1.108–85.636, p = 0.040). Addition of JAK2 inhibitors to TKI therapy did not significantly improve molecular responses over TKI monotherapy (67.1% vs. 54.8%, p = 0.193). To summarize, prior BCR::ABL1 ‐negative MPN, the most frequent presentation, predicted inferior molecular responses. Clinicians should screen for coexistent mutations if cytosis persisted despite treatment. TKI remained the therapeutic cornerstone, as combined JAK2 inhibition demonstrated limited additional benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fusion Proteins, bcr-ablLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMyeloproliferative DisordersProto-Oncogene Proteins c-ablHumansRetrospective StudiesFemaleMaleMiddle AgedAgedAdultAged, 80 and overJanus Kinase 2Prognosis

Stichwörter der Autor:innen

chronic myeloid leukemiaclinical characteristicscoexistentmyeloproliferative neoplasmretrospective

Substanzen

Fusion Proteins, bcr-ablProto-Oncogene Proteins c-ablJanus Kinase 2

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical…
  • MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Department of Hematology, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, China.
  • Tianjin Institutes of Health Science, Tianjin, China.

ORCID-Profile: Yanan Cai, Bing Li, Zhijian Xiao

Förderung

  • National Natural Science Funds
  • Foundation of Tianjin Municipal Health Commission

Zitieren

APA

Cai, Y., Xu, Z., Qu, S., Pan, L., Gao, Q., Jiao, M., Zhao, S., Li, F., Liu, N., Zhu, Z., Li, B., Xiao, Z., & Qin, T. (2026). Clinical Characteristics of Coexistent Chronic Myeloid Leukemia and BCR::ABL1 Negative Myeloproliferative Neoplasms: A Retrospective Study. Hematological Oncology. https://doi.org/10.1002/hon.70273

Vancouver

Cai Y, Xu Z, Qu S, Pan L, Gao Q, Jiao M, et al. Clinical Characteristics of Coexistent Chronic Myeloid Leukemia and BCR::ABL1 Negative Myeloproliferative Neoplasms: A Retrospective Study. Hematological Oncology. 2026. doi:10.1002/hon.70273

BibTeX
@article{Cai2026,
  author = {Cai, Yanan and Xu, Zefeng and Qu, Shiqiang and Pan, Lijuan and Gao, Qingyan and Jiao, Meng and Zhao, Songyang and Li, Fuhui and Liu, Ningning and Zhu, Zunmin and Li, Bing and Xiao, Zhijian and Qin, Tiejun},
  title = {Clinical Characteristics of Coexistent Chronic Myeloid Leukemia and BCR::ABL1 Negative Myeloproliferative Neoplasms: A Retrospective Study},
  journal = {Hematological Oncology},
  year = {2026},
  doi = {10.1002/hon.70273}
}
Kostenlos starten →